Skip to content

Omeros OMER Total debt

Discontinued — last reported Q4 '25

Total debt at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.38M+29.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$83.16M-17.1%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
Vor Biopharma logo
Vor BiopharmaVOR
$2.94M-90.5%
Annexon logo
AnnexonANNX
$25.43M-10.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$113M+88.3%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

Plus components not separately reported this period.

The official record: Omeros’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's total debt?
Omeros (OMER) reported total debt of $13.55M in Q4 2025.
How has Omeros's total debt changed year-over-year?
Omeros's total debt decreased by 30.3% year-over-year, from $19.44M to $13.55M.
What is the long-term trend for Omeros's total debt?
Over 5 years (2020 to 2025), Omeros's total debt has grown at a -16.1% compound annual growth rate (CAGR), from $32.55M to $13.55M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.